HYPERCHOLESTEROLEMIA
Clinical trials for HYPERCHOLESTEROLEMIA explained in plain language.
Never miss a new study
Get alerted when new HYPERCHOLESTEROLEMIA trials appear
Sign up with your email to follow new studies for HYPERCHOLESTEROLEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stubborn high cholesterol: pemafibrate trial launches
Disease control Not yet recruitingThis study tests a drug called pemafibrate in 120 adults with high cholesterol that remains high even after taking statins. Participants will take either a low or higher dose of pemafibrate or a placebo pill daily for 12 weeks. The goal is to see if pemafibrate can safely lower c…
Matched conditions: HYPERCHOLESTEROLEMIA
Phase: PHASE4 • Sponsor: Kowa Company, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Heart-Health drug combo tested to ward off dementia in High-Risk group
Disease control Not yet recruitingThis small pilot study will test a pharmacist-led program to control high blood pressure and cholesterol in 10 people aged 50-75 who carry the APOE ε4 gene, a major risk factor for Alzheimer's. Participants will take specific medications for six months to see if managing these he…
Matched conditions: HYPERCHOLESTEROLEMIA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Triple cholesterol punch: could three drugs beat two after a heart attack?
Disease control Not yet recruitingThis study compares a three-drug combination (atorvastatin, ezetimibe, and bempedoic acid) against the usual two-drug therapy for lowering LDL cholesterol in people who have had a heart attack or unstable angina. About 120 adults will take either the triple or dual therapy for 3 …
Matched conditions: HYPERCHOLESTEROLEMIA
Phase: PHASE4 • Sponsor: Punjab Institute of Cardology • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Triple-Drug cocktail aims to reverse early heart disease
Disease control Not yet recruitingThis Phase 3 trial will test whether a combination of three cholesterol-lowering drugs—bempedoic acid, ezetimibe, and a high-intensity statin—can reduce and stabilize plaque buildup in the coronary arteries. The study enrolls 103 adults with coronary atherosclerosis who have neve…
Matched conditions: HYPERCHOLESTEROLEMIA
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Cholesterol drug showdown: which one do patients actually take?
Knowledge-focused Not yet recruitingThis study will look at medical records from 3,600 people in Japan to see how well they follow their prescribed cholesterol-lowering medication. It compares two drugs, inclisiran and evolocumab, over 12 months. The goal is to understand real-world adherence, not to test new treat…
Matched conditions: HYPERCHOLESTEROLEMIA
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Digital nudge: could a letter save your heart?
Knowledge-focused Not yet recruitingThis study tests whether sending an electronic letter to people with heart disease and high cholesterol encourages them to get their cholesterol checked. Researchers will compare those who receive the letter to those who don't, using national health records to track results. The …
Matched conditions: HYPERCHOLESTEROLEMIA
Phase: NA • Sponsor: Tor Biering-Sørensen • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Health coaches to the rescue: can community workers help patients manage multiple illnesses?
Knowledge-focused Not yet recruitingThis study will see if community health workers (CHWs) can help people with two or more chronic conditions like diabetes, high blood pressure, or heart disease better manage their health. About 300 adults who are medically underserved will work with a CHW to create a personal hea…
Matched conditions: HYPERCHOLESTEROLEMIA
Phase: NA • Sponsor: Meharry Medical College • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC